Depuy's Strategy for a New Orthopedics Market
As managed care makes its presence felt, the question orthopedic companies face isn't whether to deal with the new players or not, but how to navigate a market sending decidedly mixed signals.
You may also be interested in...
In the US acceptance of dynamic stabilization devices (DYNs) has been strong owing to the compelling advantages of DYNs over artificial discs, including that they can be implanted from a posterior route, do not violate the disc space and the procedure is reversible. Rather being an alternative to fusion, artificial discs will likely compete with DYNs.
A conservative industry, orthopedics rarely sees a lot of acquisition activity. But a number of deals among spine companies recently underscores how hot the spine market is right now and the importance of acquisition as a strategy for realizing its potential.
The RNA drug’s accelerated approval brings Sarepta’s exon-skipping market share to nearly 30%.